Effects of exenatide in poorly controlled type 2 diabetes

QJM: An International Journal of Medicine

Volumn 105, Issue 4, 2012, Pages 321-326

  Kaimal, N ^a   Schofield, J ^a   Zaki, A ^a   Patel, R ^a   Sharma, M ^a   Mccourt, E ^a   Imtiaz, K E ^a  

^a Chorley and South Ribble Hospital ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHASIC INSULIN; EXENDIN 4; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PANCREATITIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 84859086750     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr180     Document Type: Article

References (20)

1. Wang SY, Chi MM, Li L, Moley KH, Wice BM. Studies with GIP/Ins cells indicate secretion by gut K cells is KATP channel independent. Am J Physiol Endcorinol Metab 2003; 284:E988-1000.
2. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24:1076-82.
3. McIntyre N, Holdsworth CD, Turner DS. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965; 25:1317-24.
4. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:3082-9.
5. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, et al. Pharmacokinetics, pharmacodynamics and safety of exenatide in patients with type 2 diabetes mellitus. Am Health Syst Pharm 2005; 62:173-81.
6. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141:1936-41.
7. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28:1083-91.
8. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092-100.
9. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Exenatide 113 Clinical Study Group. Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628-35.
10. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8:436-47.
11. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients With type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007; 30:2767-72.
12. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 2009; 25:65-75.
13. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulphonylurea and metformin. Diabetologia 2007; 50:259-67.
14. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143:559-69.
15. Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009; 11:1153-62.
16. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3:153-65.
17. Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, et al. One year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32:762-8.
18. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009; 31:1511-23.
19. Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract 2008; 14:28592.
20. Viswanathan P, Chaudhuri A, Bhatia R, et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 2007; 13:444-50.